Phase IIb trial of FV 100 in patients with herpes zoster infections

Trial Profile

Phase IIb trial of FV 100 in patients with herpes zoster infections

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Valnivudine (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors ContraVir Pharmaceuticals
  • Most Recent Events

    • 09 Dec 2014 Status changed from planning to not yet recruiting, according to a ContraVir Pharmaceuticals media release.
    • 08 Jul 2014 ContraVir Pharmaceuticals now plans to initiate this phase IIb trial. ContraVir Pharmaceuticals spin off of Synergy Pharmaceuticals and became an independent public company in January 2014.
    • 08 Jul 2014 Planned initiation date changed from 1 Jun 2012 to 1 Oct 2014 according to a ContraVir Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top